These included ATM, CDH1, CHEK2, and RAD51D in cases of bilateral breast cancer and CHK2, MHS6 and NBN in those with ovarian cancer.93 Lee and colleagues similarly reported the occurrence of MSH2, PMS2, and CHEK2 in four hereditary breast and ovarian cancer syndrome patients with a family history of cancer.94 This highlights the importance of multi-gene panel testing as a follow-on test for those with incomplete testing. This evidence concerns the gene CHEK2 and breast cancer.